FY2027 EPS Forecast for Janux Therapeutics Lifted by Analyst

Janux Therapeutics, Inc. (NASDAQ:JANX) – Analysts at HC Wainwright increased their FY2027 EPS estimates for Janux Therapeutics in a note issued to investors on Tuesday, December 3rd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($2.38) for the year, up from their prior estimate of ($2.48). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Janux Therapeutics’ FY2028 earnings at ($0.22) EPS.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Janux Therapeutics’s quarterly revenue was down 82.6% on a year-over-year basis.

Other analysts have also recently issued research reports about the company. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. UBS Group initiated coverage on Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective on the stock. Scotiabank boosted their target price on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research note on Wednesday. BTIG Research raised their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Leerink Partners boosted their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $79.90.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $64.99 on Thursday. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of -56.67 and a beta of 3.29. Janux Therapeutics has a one year low of $7.79 and a one year high of $71.71. The company’s 50-day simple moving average is $50.60 and its 200-day simple moving average is $46.10.

Insider Activity at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $46.24, for a total value of $44,297.92. Following the sale, the insider now directly owns 6,887 shares in the company, valued at $318,454.88. This trade represents a 12.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00. Following the sale, the chief executive officer now directly owns 307,054 shares in the company, valued at $14,219,670.74. The trade was a 7.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 352,245 shares of company stock worth $17,032,336 in the last ninety days. 29.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after buying an additional 378,477 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Janux Therapeutics during the first quarter worth approximately $739,000. DNB Asset Management AS acquired a new stake in Janux Therapeutics in the second quarter worth approximately $221,000. SG Americas Securities LLC bought a new position in Janux Therapeutics during the 2nd quarter valued at $1,452,000. Finally, Bank of New York Mellon Corp increased its position in shares of Janux Therapeutics by 136.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 115,027 shares of the company’s stock valued at $4,818,000 after purchasing an additional 66,340 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.